Caribou Biosciences Inc (NASDAQ: CRBU) on Friday, plunged -9.45% from the previous trading day, before settling in for the closing price of $2.75. Within the past 52 weeks, CRBU’s price has moved between $0.66 and $3.00.
Healthcare Sector giant saw their annual sales slid by -33.41% over the last five years. The company achieved an average annual earnings per share of 0.06%. With a float of $82.13 million, this company’s outstanding shares have now reached $93.12 million.
Caribou Biosciences Inc (CRBU) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Caribou Biosciences Inc is 11.80%, while institutional ownership is 40.84%. The most recent insider transaction that took place on Mar 14 ’25, was worth 20,400. In this transaction President and CEO of this company bought 20,000 shares at a rate of $1.02, taking the stock ownership to the 3,369,395 shares. Before that another transaction happened on Feb 21 ’25, when Company’s Chief Legal Officer sold 3,564 for $1.35, making the entire transaction worth $4,811. This insider now owns 443,502 shares in total.
Caribou Biosciences Inc (CRBU) Earnings and Forecasts
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.38 earnings per share (EPS) for the period topping the consensus outlook (set at -0.45) by 0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 0.06% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.99% during the next five years compared to -33.41% drop over the previous five years of trading.
Caribou Biosciences Inc (NASDAQ: CRBU) Trading Performance Indicators
Caribou Biosciences Inc (CRBU) is currently performing well based on its current performance indicators. A quick ratio of 6.66 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 25.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.79, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach -1.40 in one year’s time.
